Guggenheim Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.74M Sell
9,215
-2,416
-21% -$422K 0.01% 746
2025
Q4
$1.98M Buy
11,631
+1,150
+11% +$176K 0.01% 677
2025
Q3
$1.38M Sell
10,481
-41
-0.4% -$4.92K 0.01% 815
2025
Q2
$1.12M Sell
10,522
-11,619
-52% -$1.26M 0.01% 847
2025
Q1
$2.75M Sell
22,141
-2,610
-11% -$340K 0.03% 557
2024
Q4
$3.05M Sell
24,751
-10,959
-31% -$1.29M 0.02% 536
2024
Q3
$3.98M Sell
35,710
-11,500
-24% -$1.26M 0.03% 600
2024
Q2
$5.04M Buy
47,210
+518
+1% +$57K 0.04% 514
2024
Q1
$5.62M Buy
46,692
+1,371
+3% +$168K 0.04% 511
2023
Q4
$5.57M Sell
45,321
-7,177
-14% -$896K 0.04% 497
2023
Q3
$6.8M Sell
52,498
-4,314
-8% -$575K 0.06% 393
2023
Q2
$7.04M Buy
56,812
+3,487
+7% +$469K 0.06% 414
2023
Q1
$7.8M Sell
53,325
-1,239
-2% -$183K 0.07% 365
2022
Q4
$8.69M Buy
54,564
+9,075
+20% +$1.33M 0.08% 331
2022
Q3
$6.06M Sell
45,489
-3,687
-7% -$561K 0.06% 427
2022
Q2
$7.67M Buy
49,176
+15,486
+46% +$2.38M 0.06% 383
2022
Q1
$5.25M Sell
33,690
-46,777
-58% -$6.79M 0.03% 630
2021
Q4
$10.3M Buy
80,467
+26,778
+50% +$3.52M 0.05% 422
2021
Q3
$6.99M Sell
53,689
-4,137
-7% -$625K 0.04% 519
2021
Q2
$10.3M Sell
57,826
-11,152
-16% -$1.93M 0.06% 392
2021
Q1
$11.3M Sell
68,978
-13,446
-16% -$2.21M 0.07% 320
2020
Q4
$13.6M Buy
82,424
+13,835
+20% +$2.06M 0.09% 241
2020
Q3
$9.78M Sell
68,589
-12,884
-16% -$1.6M 0.07% 291
2020
Q2
$8.99M Buy
81,473
+15,362
+23% +$1.7M 0.07% 297
2020
Q1
$6.59M Sell
66,111
-14,716
-18% -$1.9M 0.07% 338
2019
Q4
$12.1M Buy
80,827
+24,941
+45% +$3.39M 0.09% 265
2019
Q3
$7.16M Sell
55,886
-2,252
-4% -$302K 0.06% 427
2019
Q2
$8.29M Sell
58,138
-6,084
-9% -$818K 0.07% 358
2019
Q1
$9.18M Sell
64,222
-16,601
-21% -$2.17M 0.07% 321
2018
Q4
$10M Sell
80,823
-9,492
-11% -$1.41M 0.08% 261
2018
Q3
$15.2M Buy
90,315
+58,563
+184% +$10.1M 0.1% 209
2018
Q2
$5.47M Buy
+31,752
New +$5.19M 0.04% 661
2018
Q1
Sell
-34,423
Closed -$5.05M 1018
2017
Q4
$4.63M Sell
34,423
-10,009
-23% -$1.39M 0.01% 1083
2017
Q3
$6.5M Buy
44,432
+10,688
+32% +$1.62M 0.02% 905
2017
Q2
$5.25M Sell
33,744
-836
-2% -$128K 0.01% 989
2017
Q1
$5.02M Sell
34,580
-8,155
-19% -$1.06M 0.01% 1019
2016
Q4
$4.66M Sell
42,735
-3,333
-7% -$371K 0.01% 1047
2016
Q3
$5.6M Buy
46,068
+13,367
+41% +$1.8M 0.02% 957
2016
Q2
$4.62M Sell
32,701
-11,045
-25% -$1.63M 0.01% 1047
2016
Q1
$5.71M Sell
43,746
-19,261
-31% -$2.4M 0.02% 917
2015
Q4
$8.86M Buy
63,007
+11,493
+22% +$1.59M 0.03% 787
2015
Q3
$6.84M Buy
51,514
+7,299
+17% +$1.26M 0.02% 908
2015
Q2
$7.79M Buy
44,215
+8,755
+25% +$1.57M 0.02% 951
2015
Q1
$6.13M Buy
35,460
+15,660
+79% +$2.69M 0.01% 1070
2014
Q4
$3.24M Buy
19,800
+5,409
+38% +$898K 0.01% 1374
2014
Q3
$2.31M Sell
14,391
-510
-3% -$78.4K 0.01% 1653
2014
Q2
$2.19M Sell
14,901
-4,381
-23% -$608K 0.01% 1728
2014
Q1
$2.67M Buy
19,282
+1,560
+9% +$235K 0.01% 1541
2013
Q4
$2.24M Sell
17,722
-2,284
-11% -$236K 0.01% 1685
2013
Q3
$1.84M Buy
+20,006
New +$1.61M 0.01% 1672

Other funds holding JAZZ

Guggenheim Capital's JAZZ Position: Q1 2026 in Review

Guggenheim Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 21% in Q1 2026, selling an estimated $422K and leaving 9,215 shares worth $1.74M. The position accounts for 0.01% of the portfolio, ranked #746.

Guggenheim Capital first reported a position in JAZZ in Q3 2013 and has held it in 50 quarters since. The position peaked at $15.2M in Q3 2018. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Guggenheim Capital held 9,215 shares of Jazz Pharmaceuticals worth $1.74M as of Q1 2026.
  • Guggenheim Capital sold 2,416 Jazz Pharmaceuticals shares in Q1 2026, an estimated $422K.
  • Jazz Pharmaceuticals made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #746 holding.
  • Guggenheim Capital first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
  • Guggenheim Capital's Jazz Pharmaceuticals position peaked at $15.2M in Q3 2018.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.